Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines

The goal of this observational study is to evaluate the efficacy and tolerability of asciminib in real-life in patients with chronic myeloid leukemia treated in second or subsequent lines. The main object of the study is to assess the achievement of Major Molecular Response.

NCT Number	NCT07640750
Lead Sponsor	Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions	Chronic Myeloid Leukemia, Chronic Myeloid Leukemia - Chronic Phase
Enrollment	98 participants
Start Date	2026-09-01
Primary Completion	2031-09-01 (estimated)
Study Completion	2031-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-11